Cargando…
Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies
The application of monoclonal antibodies (mAbs) for the treatment of melanoma has significantly improved the clinical management of this malignancy over the last decade. Currently approved mAbs for melanoma enhance T cell effector immune responses by blocking immune checkpoint molecules PD-L1/PD-1 a...
Autores principales: | Adams, Rebecca, Osborn, Gabriel, Mukhia, Bipashna, Laddach, Roman, Willsmore, Zena, Chenoweth, Alicia, Geh, Jenny L C, MacKenzie Ross, Alastair D, Healy, Ciaran, Barber, Linda, Tsoka, Sophia, Sanz-Moreno, Victoria, Lacy, Katie E, Karagiannis, Sophia N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543025/ https://www.ncbi.nlm.nih.gov/pubmed/36211808 http://dx.doi.org/10.1080/2162402X.2022.2127284 |
Ejemplares similares
-
Enriched circulating and tumor-resident TGF-β(+) regulatory B cells in patients with melanoma promote FOXP3(+) Tregs
por: Harris, Robert J, et al.
Publicado: (2022) -
B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies
por: Willsmore, Zena N., et al.
Publicado: (2021) -
B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma
por: Crescioli, Silvia, et al.
Publicado: (2023) -
Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies
por: Osborn, Gabriel, et al.
Publicado: (2021) -
Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4
por: Chauhan, Jitesh, et al.
Publicado: (2023)